• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by IDEXX Laboratories Inc.

    4/30/26 10:29:02 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $IDXX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    IDEXX Laboratories Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)




    45168D104

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    45168D104


    1Names of Reporting Persons

    Vanguard Capital Management
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    793,965.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    5,976,472.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,976,472.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.51 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:   In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd. This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power. This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    IDEXX Laboratories Inc
    (b)Address of issuer's principal executive offices:

    One Idexx Drive, Westbrook, ME, 04092
    Item 2. 
    (a)Name of person filing:

    Vanguard Capital Management
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd,, Malvern, PA, 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP Number(s):

    45168D104
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    5976472
    (b)Percent of class:

    7.51  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    793965

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    5976472

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Vanguard Capital Management, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Vanguard Capital Management
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:04/30/2026
    Get the next $IDXX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IDXX

    DatePrice TargetRatingAnalyst
    4/15/2026$650.00Neutral
    Citigroup
    12/9/2025$850.00Overweight
    Barclays
    10/31/2025$700.00Hold → Buy
    Stifel
    10/1/2025$720.00Neutral
    UBS
    8/5/2025$545.00 → $785.00Buy
    BTIG Research
    7/1/2025$625.00Buy
    Jefferies
    12/2/2024$500.00Outperform
    Leerink Partners
    7/25/2024$580.00Buy
    BTIG Research
    More analyst ratings

    $IDXX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IDEXX Expands Fecal Dx Antigen Testing Platform with Taeniid Tapeworm Detection

    Third menu expansion in four years broadens intestinal parasite detection in routine care IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the expansion of its Fecal Dx™ antigen testing platform with taeniid tapeworm, including Taenia and Echinococcus species. Proven to detect up to twice as many intestinal parasite infections earlier than fecal flotation alone,1 Fecal Dx antigen testing delivers broader parasite detection in a single test for both wellness and sick-pet care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526203257/en/IDEXX Fecal Dx™ antigen testing platf

    5/26/26 7:00:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles

    Built-in SDMA delivers earlier insights with seamless workflow IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced that SDMA, a renal biomarker, will be built into Catalyst™ CLIPs, making complete kidney function evaluation part of the most common point-of-care chemistry profiles. Available beginning in June to customers in the United States and Canada, the integration expands access to advanced kidney assessment at scale, enabling veterinarians to identify kidney function loss earlier and act sooner, without disrupting familiar workflows. This press release features multimedia. View the full release here: https://www.businesswire.com/new

    5/19/26 7:00:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    The Biology Came First.

    Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company's work today. MindWalk Holdings Corp. (NASDAQ:HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, the clinical asset is

    5/18/26 8:34:00 AM ET
    $ARGX
    $CGEM
    $HYFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $IDXX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on IDEXX Labs with a new price target

    Citigroup initiated coverage of IDEXX Labs with a rating of Neutral and set a new price target of $650.00

    4/15/26 8:08:55 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Barclays initiated coverage on IDEXX Labs with a new price target

    Barclays initiated coverage of IDEXX Labs with a rating of Overweight and set a new price target of $850.00

    12/9/25 8:50:15 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IDEXX Labs upgraded by Stifel with a new price target

    Stifel upgraded IDEXX Labs from Hold to Buy and set a new price target of $700.00

    10/31/25 8:14:50 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $IDXX
    SEC Filings

    View All

    $IDXX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form SD filed by IDEXX Laboratories Inc.

    SD - IDEXX LABORATORIES INC /DE (0000874716) (Filer)

    6/1/26 4:00:04 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IDEXX Laboratories Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)

    5/15/26 4:00:10 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 10-Q filed by IDEXX Laboratories Inc.

    10-Q - IDEXX LABORATORIES INC /DE (0000874716) (Filer)

    5/5/26 4:14:10 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Executive Vice President Fennell George converted options into 639 shares and covered exercise/tax liability with 284 shares, increasing direct ownership by 4% to 10,433 units (SEC Form 4)

    4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)

    6/2/26 5:00:13 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Director Samad Sam

    4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)

    5/14/26 5:00:55 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Director Vandebroek Sophie V.

    4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)

    5/14/26 5:01:01 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $IDXX
    Financials

    Live finance-specific insights

    View All

    IDEXX Laboratories Announces First Quarter Results

    Achieves first quarter revenue growth of 14% as reported and 11% organic, and CAG Diagnostics recurring revenue growth of 14% as reported and 11% organic. Double-digit organic revenue growth was driven by IDEXX execution and commercial performance, reflecting strong volume growth and benefits from IDEXX's innovation. Delivers EPS of $3.47, an increase of 17% as reported and 15% on a comparable basis, including operating margin expansion of 10 basis points as reported and 100 basis points on a comparable basis. Increases 2026 revenue guidance to $4,675 million - $4,760 million, up $42 million or ~1% at midpoint, reflecting stronger CAG Diagnostics recurring revenue performance.

    5/5/26 6:30:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IDEXX Laboratories to Release 2026 First Quarter Financial Results

    IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 first quarter financial results for Tuesday, May 5, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q1 2026 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen to

    4/8/26 1:00:00 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results

    Achieves fourth quarter revenue growth of 14% as reported and 12% organic, reflecting strong CAG Diagnostics recurring revenue, growing 12% reported and 10% organic. Strong organic growth benefits from IDEXX execution and commercial performance, including over 1,900 IDEXX inVue Dx™ placements, delivering a quarterly record of instrument placements and 12% year-over-year expansion of IDEXX's global premium instrument installed base. Delivers fourth quarter EPS of $3.08, an increase of 18% as reported and 17% on a comparable basis, supported by operating margin expansion of 150 basis points as reported and 120 basis points on a comparable basis. Provides initial outlook for 2026 re

    2/2/26 6:30:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $IDXX
    Leadership Updates

    Live Leadership Updates

    View All

    Bonsai Health Names ModMed Veteran Rick Trefzger Chief Revenue Officer

    Former Modernizing Medicine sales leader joins Bonsai to accelerate growth of its agentic AI platform for healthcare practices. Bonsai Health, the agentic AI platform automating complex healthcare workflows, today announced that Rick Trefzger has joined the company as Chief Revenue Officer (CRO). Trefzger joins Bonsai after nearly 11 years at Modernizing Medicine (ModMed), where he was an early employee and served as vice president of sales, helping scale the company into the leading specialty-specific EHR platform serving dermatology, ophthalmology, orthopedics, gastroenterology, and other core specialties. During his tenure, ModMed grew into one of the most widely adopted specialty te

    10/16/25 7:00:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IDEXX Laboratories Elects Karen Peacock to Board of Directors

    IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the election of Karen Peacock to the Company's Board of Directors, effective October 6, 2025. "We are extremely pleased to welcome Karen to the IDEXX Board of Directors," said Lawrence D. Kingsley, the Company's Independent Non-Executive Board Chair. "Karen is a highly accomplished executive with deep B2B, SaaS software and AI experience gained through building and running software and technology companies at various lifecycle stages. We are confident that her extensive professional experience and skills will complement those of our other Board members and contribute to our Board's overal

    10/7/25 7:00:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IDEXX Laboratories Elects Joseph L. (Jay) Hooley to Board of Directors

    IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the election of Joseph L. (Jay) Hooley to the Company's Board of Directors, effective July 10, 2025. "We are excited to welcome Jay to the IDEXX Board of Directors," said Lawrence D. Kingsley, the Company's Independent Non-Executive Board Chair. "Jay is an accomplished executive who brings extensive strategic thinking and financial leadership experience, along with investor perspective, from his tenure leading State Street during a period of global growth and technological transformation. Given his substantial public company board and corporate governance experience and his unique backgro

    7/10/25 7:00:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $IDXX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by IDEXX Laboratories Inc.

    SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

    11/12/24 3:48:28 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by IDEXX Laboratories Inc.

    SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

    11/4/24 11:47:05 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by IDEXX Laboratories Inc. (Amendment)

    SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

    2/13/24 5:06:19 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care